Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US Business Published: 11/26/2022 Reading time: Less than 1 min. FacebookTwitterWhatsAppLinkedinCopy URL The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN). Join Our Telegram Group for Job updates & Startup news LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment. FacebookTwitterWhatsAppLinkedinCopy URL Himanshi Related articles Google Search Gets a Spring Cleaning: March 2024 Core Update Targets Unhelpful Content Stories of Corporates 03/19/2024 Unbreakable: The Remarkable Journey of Paul Alexander Stories of Corporates 03/18/2024 OpenAI Shakes Up Governance: Sam Altman Returns and New Board Members Appointed Stories of Corporates 03/12/2024 Introducing Einstein GPT: Salesforce’s game-changing AI for CRM (Customer Relationship Management) Stories of Corporates 03/05/2024 Recent articles Google Search Gets a Spring Cleaning: March 2024 Core Update Targets Unhelpful Content Stories of Corporates 03/19/2024 Unbreakable: The Remarkable Journey of Paul Alexander Stories of Corporates 03/18/2024 OpenAI Shakes Up Governance: Sam Altman Returns and New Board Members Appointed Stories of Corporates 03/12/2024 Introducing Einstein GPT: Salesforce’s game-changing AI for CRM (Customer Relationship Management) Stories of Corporates 03/05/2024